Paion AG
PA8
Rang in aandelen
#35735
Paion AG is a specialized pharmaceutical firm engaged in the global development... Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.
Aandeelprijs
$0.42701586
Laatst gesynchroniseerd: 2023-11-01
Marktkapitalisatie
$3.21M
Verandering (1 dag)
16.99%
Verandering (1 jaar)
3,295.00%
Land
DE
Handel Paion AG (PA8)
Categorie
Healthcare
Koersgeschiedenis voor Paion AG (PA8)
Hoogste slotkoers: $0.01 op 2025-09-01
Laagste slotkoers: $7.36 op 2023-03-01
Laagste slotkoers: $7.36 op 2023-03-01
Koersgeschiedenis van Paion AG van 2023 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2025 | -20.23% |
| 2024 | -93.11% |
| 2023 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $162.72 | 21.69% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $225.11 | 31.46% |
CH
|
|
| $18.43 | -4.03% |
IN
|
